Gut immune cells-A novel therapeutical target for cardiovascular disease?
GLP-1
atherosclerosis
cardiovascular disease
gut immune cells
heart failure
integrin β7
intraepithelial lymphocytes
myocardial infarction
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
05
2022
accepted:
01
08
2022
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
2
9
2022
Statut:
epublish
Résumé
Despite scientific and clinical advances during the last 50 years cardiovascular disease continues to be the main cause of death worldwide. Especially patients with diabetes display a massive increased cardiovascular risk compared to patients without diabetes. Over the last two decades we have learned that cardiometabolic and cardiovascular diseases are driven by inflammation. Despite the fact that the gastrointestinal tract is one of the largest leukocyte reservoirs of our bodies, the relevance of gut immune cells for cardiovascular disease is largely unknown. First experimental evidence suggests an important relevance of immune cells in the intestinal tract for the development of metabolic and cardiovascular disease in mice. Mice specifically lacking gut immune cells are protected against obesity, diabetes, hypertension and atherosclerosis. Importantly antibody mediated inhibition of leukocyte homing into the gut showed similar protective metabolic and cardiovascular effects. Targeting gut immune cells might open novel therapeutic approaches for the treatment of cardiometabolic and cardiovascular diseases.
Identifiants
pubmed: 36046186
doi: 10.3389/fcvm.2022.943214
pmc: PMC9421162
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
943214Subventions
Organisme : NHLBI NIH HHS
ID : R35 HL135752
Pays : United States
Informations de copyright
Copyright © 2022 Ganesh, van der Vorst, Spiesshöfer, He, Burgmaier, Findeisen, Lehrke, Swirski, Marx and Kahles.
Déclaration de conflit d'intérêts
Author FK served as a consultant to Bayer and Novo Nordisk and served as a speaker for Novo Nordisk. Author NM has received support for clinical trial leadership from Boehringer Ingelheim, Novo Nordisk, served as a consultant to Bayer, Boehringer Ingelheim, Merck, Novo Nordisk, AstraZeneca, BMS, received grant support from Boehringer Ingelheim, Merck, Novo Nordisk, and served as a speaker for Bayer, Boehringer Ingelheim, Merck, Novo Nordisk, Lilly, BMS, and AstraZeneca. Author ML received grants and personal fees from Boehringer Ingelheim, MSD, Novo Nordisk and personal fees from Amgen, Sanofi, Astra Zeneca, Bayer, Lilly, Daiichi Sankyo, Novarits, Amarin. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2012 Jan 5;366(1):54-63
pubmed: 22216842
N Engl J Med. 2017 Apr 13;376(15):1407-1418
pubmed: 28402770
Microorganisms. 2022 Jan 05;10(1):
pubmed: 35056557
N Engl J Med. 2019 Aug 29;381(9):841-851
pubmed: 31185157
Curr Mol Med. 2009 Sep;9(7):836-50
pubmed: 19860663
Lancet. 2020 Sep 19;396(10254):819-829
pubmed: 32877652
Nature. 2012 Jul 19;487(7407):325-9
pubmed: 22763456
Lancet. 2019 Jul 13;394(10193):121-130
pubmed: 31189511
Nat Commun. 2021 May 10;12(1):2598
pubmed: 33972511
JAMA. 1987 May 1;257(17):2318-24
pubmed: 3553628
Science. 2013 Jan 11;339(6116):161-6
pubmed: 23307733
Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662
pubmed: 34425083
Immunol Rev. 1997 Apr;156:145-66
pubmed: 9176706
Cell Metab. 2015 Jul 7;22(1):113-24
pubmed: 26094890
Cell. 1989 Jan 13;56(1):37-46
pubmed: 2463092
Am J Physiol Heart Circ Physiol. 2020 Dec 1;319(6):H1227-H1233
pubmed: 32986965
J Clin Invest. 2017 Jan 3;127(1):33-42
pubmed: 28045403
Lancet. 2017 Jul 8;390(10090):135-144
pubmed: 28527704
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Cell Metab. 2015 Apr 7;21(4):527-42
pubmed: 25863246
Diabetes. 2014 Oct;63(10):3221-9
pubmed: 24947356
Cardiovasc Diabetol. 2013 Aug 16;12:117
pubmed: 23953602
Diabetes. 2015 Jul;64(7):2537-49
pubmed: 25735732
J Exp Med. 1985 Mar 1;161(3):475-89
pubmed: 3973536
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
Lancet. 2018 Oct 27;392(10157):1519-1529
pubmed: 30291013
N Engl J Med. 2013 Aug 22;369(8):699-710
pubmed: 23964932
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Nat Commun. 2019 Aug 13;10(1):3650
pubmed: 31409776
Cell Metab. 2016 Jul 12;24(1):15-30
pubmed: 27345422
J Am Coll Cardiol. 2002 Nov 20;40(10):1761-8
pubmed: 12446059
Nat Rev Immunol. 2011 Jun 17;11(7):445-56
pubmed: 21681197
J Am Coll Cardiol. 2009 Dec 1;54(23):2129-38
pubmed: 19942084
N Engl J Med. 1999 Jan 14;340(2):115-26
pubmed: 9887164
Nat Med. 2011 Oct 30;17(11):1481-9
pubmed: 22037645
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140
pubmed: 34798039
Curr Opin Lipidol. 2012 Dec;23(6):569-75
pubmed: 23069986
N Engl J Med. 2020 Nov 5;383(19):1838-1847
pubmed: 32865380
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1924-8
pubmed: 1542691
Nat Immunol. 2022 Apr;23(4):605-618
pubmed: 35352063
Nature. 2019 Feb;566(7742):115-119
pubmed: 30700910
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
PLoS One. 2015 Apr 02;10(4):e0122195
pubmed: 25837594
BMJ Open. 2013 Sep 03;3(9):e003201
pubmed: 24002982
Am J Med. 2017 Jul;130(7):833-841.e3
pubmed: 28366423
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Gastroenterol Clin North Am. 1991 Sep;20(3):549-76
pubmed: 1917026
N Engl J Med. 2005 Apr 21;352(16):1685-95
pubmed: 15843671
J Clin Invest. 2015 Apr;125(4):1752-62
pubmed: 25751065
Cell Metab. 2015 Jul 7;22(1):100-12
pubmed: 26154056
Diabetes Obes Metab. 2018 Dec;20(12):2911-2918
pubmed: 30033664
Gastroenterology. 2007 May;132(6):2131-57
pubmed: 17498508
Circ J. 2015;79(9):1882-90
pubmed: 26212124
N Engl J Med. 2000 Mar 23;342(12):836-43
pubmed: 10733371
EMBO J. 1989 Jun;8(6):1735-41
pubmed: 2670559
N Engl J Med. 2021 Sep 2;385(10):896-907
pubmed: 34215025
Eur Heart J. 2020 Feb 14;41(7):882-889
pubmed: 31620788
Expert Opin Biol Ther. 2020 Apr;20(4):437-442
pubmed: 31709847